AR126537A1 - Sales y formas en estado sólido de un compuesto inhibidor de kif18a - Google Patents
Sales y formas en estado sólido de un compuesto inhibidor de kif18aInfo
- Publication number
- AR126537A1 AR126537A1 ARP220101934A ARP220101934A AR126537A1 AR 126537 A1 AR126537 A1 AR 126537A1 AR P220101934 A ARP220101934 A AR P220101934A AR P220101934 A ARP220101934 A AR P220101934A AR 126537 A1 AR126537 A1 AR 126537A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- salt
- hcl
- solid form
- cocrystal
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000007787 solid Substances 0.000 title abstract 5
- 101001091231 Homo sapiens Kinesin-like protein KIF18A Proteins 0.000 title 1
- 229940126262 KIF18A Drugs 0.000 title 1
- 102100034895 Kinesin-like protein KIF18A Human genes 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 229940126062 Compound A Drugs 0.000 abstract 5
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 239000012453 solvate Substances 0.000 abstract 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- KBDGEJDIHZDPHN-UHFFFAOYSA-N 2-(6-azaspiro[2.5]octan-6-yl)-N-[2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl]-4-(2-hydroxyethylsulfonylamino)benzamide Chemical compound FC1(CCN(CC1)C1=NC(=CC(=N1)NC(C1=C(C=C(C=C1)NS(=O)(=O)CCO)N1CCC2(CC2)CC1)=O)C)F KBDGEJDIHZDPHN-UHFFFAOYSA-N 0.000 abstract 1
- 102000010638 Kinesin Human genes 0.000 abstract 1
- 108010063296 Kinesin Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 150000003840 hydrochlorides Chemical class 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
En el presente documento, se divulga una sal, una forma anhidra cristalina, un hidrato, un solvato o un cocristal de un compuesto de base libre 2-(6-azaespiro[2.5]octan-6-il)-N-[2-(4,4-difluoropiperidin-1-il)-6-metilpirimidin-4-il]-4-[(2-hidroxietanosulfonil)amino]benzamida (Compuesto A); un método de preparación, composiciones farmacéuticas y un método de tratamiento de una enfermedad mediada por la inhibición de un miembro 18A de la familia de la proteína motora cinesina (KIF18A), en donde dicha enfermedad es una enfermedad neoplásica, incluyendo un cáncer o un tumor. Reivindicación 1: Una sal, un hidrato, un solvato o un cocristal del Compuesto A que tiene una estructura química de fórmula (A); o una forma sólida del Compuesto A, incluyendo las formas anhidras cristalinas, la sal, el solvato o el cocristal del mismo. Reivindicación 14: Una composición farmacéutica que comprende la forma sólida del Compuesto A-HCl de una cualquiera de las reivindicaciones 2 a 12, o la sal HCl del Compuesto A de acuerdo con la reivindicación 13, y un excipiente farmacéuticamente aceptable. Reivindicación 19: Un método para preparar la sal del Compuesto A-HCl o la forma sólida del mismo de la reivindicación 2, comprendiendo el método: combinar ácido clorhídrico, Compuesto A y un disolvente adecuado para formar el Compuesto A-HCl o la forma sólida del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163224208P | 2021-07-21 | 2021-07-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126537A1 true AR126537A1 (es) | 2023-10-18 |
Family
ID=83148993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101934A AR126537A1 (es) | 2021-07-21 | 2022-07-21 | Sales y formas en estado sólido de un compuesto inhibidor de kif18a |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4373818A1 (es) |
| KR (1) | KR20240051338A (es) |
| CN (1) | CN117940416A (es) |
| AR (1) | AR126537A1 (es) |
| AU (1) | AU2022313961A1 (es) |
| CA (1) | CA3226614A1 (es) |
| IL (1) | IL310234A (es) |
| TW (1) | TW202321213A (es) |
| UY (1) | UY39866A (es) |
| WO (1) | WO2023004075A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116903605A (zh) * | 2022-04-15 | 2023-10-20 | 武汉人福创新药物研发中心有限公司 | 一种kif18a抑制剂及其用途 |
| CN116535400A (zh) * | 2023-04-26 | 2023-08-04 | 上海湃隆生物科技有限公司 | 氮杂螺环化合物及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8576985B2 (en) | 2009-09-01 | 2013-11-05 | Aptuit (West Lafayette) Llc | Methods for indexing solid forms of compounds |
| US11236069B2 (en) | 2018-12-20 | 2022-02-01 | Amgen Inc. | KIF18A inhibitors |
| JP2023521802A (ja) * | 2020-04-14 | 2023-05-25 | アムジエン・インコーポレーテツド | 新生物疾患の処置のためのｋｉｆ１８ａ阻害剤 |
-
2022
- 2022-07-18 TW TW111126873A patent/TW202321213A/zh unknown
- 2022-07-21 UY UY0001039866A patent/UY39866A/es unknown
- 2022-07-21 EP EP22761662.0A patent/EP4373818A1/en active Pending
- 2022-07-21 CN CN202280060739.4A patent/CN117940416A/zh active Pending
- 2022-07-21 AU AU2022313961A patent/AU2022313961A1/en active Pending
- 2022-07-21 WO PCT/US2022/037928 patent/WO2023004075A1/en active Application Filing
- 2022-07-21 IL IL310234A patent/IL310234A/en unknown
- 2022-07-21 AR ARP220101934A patent/AR126537A1/es unknown
- 2022-07-21 KR KR1020247005985A patent/KR20240051338A/ko unknown
- 2022-07-21 CA CA3226614A patent/CA3226614A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240051338A (ko) | 2024-04-19 |
| CN117940416A (zh) | 2024-04-26 |
| AU2022313961A1 (en) | 2024-02-08 |
| IL310234A (en) | 2024-03-01 |
| WO2023004075A1 (en) | 2023-01-26 |
| EP4373818A1 (en) | 2024-05-29 |
| CA3226614A1 (en) | 2023-01-26 |
| TW202321213A (zh) | 2023-06-01 |
| UY39866A (es) | 2023-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126537A1 (es) | Sales y formas en estado sólido de un compuesto inhibidor de kif18a | |
| KR101866858B1 (ko) | Lsd1의 아릴사이클로프로필아민 기반 디메틸라아제 억제제 및 이의 의학적 이용 | |
| US7105567B2 (en) | 3-substituted urea derivatives and medicinal use thereof | |
| PE20231438A1 (es) | Proceso para hacer un inhibidor de pd-1/pd-l1 y sales y formas cristalinas del mismo | |
| EA202092169A1 (ru) | ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ АМИНОПРОПИОНАТНЫХ СОЕДИНЕНИЙ В ЛЕЧЕНИИ ИНФЕКЦИИ SARS-CoV-2 | |
| CR20220456A (es) | Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead | |
| BRPI0015610C1 (pt) | composto derivado de 3,3-difenilpropilamina, processo para preparação do mesmo, utilização de intermediários na obtenção do referido composto | |
| WO2000075113A1 (fr) | Nouveaux derives carboxamide heterocycliques | |
| BRPI0407618A (pt) | derivados de tiazole amino substituidos com cicloalquilo contendo n e composições farmacêuticas para inibição da proliferação celular e métodos para a sua utilização | |
| AR030959A1 (es) | Derivados de aminoalcoholes, procedimiento para prepararlos, el uso de los mismos para preparar medicamentos y las composiciones farmaceuticas que las contienen | |
| CA3037369A1 (en) | Yap1 inhibitors that target the interaction of yap1 with oct4 | |
| WO2005097764A1 (ja) | チアゾール誘導体 | |
| JP7433292B2 (ja) | １０ｈ－フェノチアジン系フェロトーシス阻害剤、その製造方法、及び用途 | |
| CA2679198A1 (en) | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
| CA2526989A1 (en) | Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors | |
| SK12162002A3 (sk) | 8,8a-Dihydroindeno [1,2-d]tiazolové driváty substituované v polohe 8a, spôsob ich prípravy a ich použitie ako liečiv | |
| AU2020303814B2 (en) | Derivative compound introducing biphenyl group into novel aminoalkanoic acid and antifungal pharmaceutical composition comprising same | |
| BR112022017398A2 (pt) | Hidrato cristalino de um composto inibidor de jak | |
| ES2215919T3 (es) | Derivados de cumarina con actividad inhibidora de comt. | |
| BR112022009705A2 (pt) | Forma cristalina anidra de um derivado de ácido 7h-benzo[7]anuleno-2-carboxílico, seus usos e processos de preparação, forma sólida, medicamento e composição farmacêutica | |
| RU2008149936A (ru) | (2r)-2-[(4-сульфонил)аминофенил]пропанамиды и содержащие их фармацевтические композиции | |
| US11130740B2 (en) | Substituted 2,3-dihydro-1H-indene analogs and methods using same | |
| ECSP23054131A (es) | Cocristal de un inhibidor de cdk | |
| US3879531A (en) | 2-aminothiazoles compositions and methods for using them as psychotherapeutic agents | |
| US20220177422A1 (en) | Remodilins for airway remodeling and organ fibrosis |